JONATHAN FALLETTA: Open Payments
NPI 1831431188 · AMHERST, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,611 in 208 payments from 19 companies in 2025. Trend: 2023 $2,316 · 2024 $3,333 · 2025 $3,611
Food & beverage: $3,499Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 41 | $659 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $532 |
| Otsuka America Pharmaceutical, Inc. | 25 | $507 |
| Neurocrine BioSciences, Inc. | 22 | $480 |
| Alkermes, Inc. | 14 | $296 |
| Vanda Pharmaceuticals Inc. | 9 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $185 |
| Lundbeck LLC | 14 | $178 |
| E.R. Squibb & Sons, L.L.C. | 12 | $167 |
| Janssen Pharmaceuticals, Inc | 5 | $88 |
Products named: CAPLYTA, REXULTI, INGREZZA, UZEDY, ARISTADA, AUSTEDO XR, FANAPT, TRINTELLIX.
Industry payments across NY — which companies pay providers there.
